CPS Presents Clinical Outcomes Research at ISPOR 2024
May 2024
The CPS team presented posters featuring health system specialty pharmacy (HSSP) clinical research and outcomes at ISPOR 2024, the leading international conference for health economics and outcomes research (HEOR).
ISPOR is a global conference for HEOR experts and thought leaders. Attendees connect to discuss how to “establish, incentivize, and share value sustainable for health systems, patients, and technology developers.”
CPS' researchers presented the following posters at this year's event. The research will also be published in ISPOR's outcomes-focused publication.
- “Enhancing Quality of Life by Transitioning from an Intravenous Infusion Treatment to a Self-Administered Medication in a Health System Specialty Pharmacy Setting.”
The authors: Jennifer Nickele, PharmD; Mitchel Riddell; Kathy Canup, PharmD; Amber Skrtic, PharmD, CSP, AAHIVP; Zel Skrtic, PharmD; Jessica Mourani, PharmD; Casey Fitzpatrick, PharmD; Carly Giavatto, PharmD; Ana Lopez Medina, PharmD.
The study helped answer the following questions: As more self-administered medications hit the market, how can HSSP teams help patients transition from provider-administered medications to the new therapies? Plus, how do patients feel about the transition afterward?
One insight: Before switching to a self-administered injectable, most patients drove at least five miles to their nearest infusion center for therapy. Self-administered therapy can help reduce travel times.
The findings: Download the poster.
- “Identifying and Addressing Social Determinants of Health (SDOH): A Health System Specialty Pharmacy Approach”
The authors: Shanece Green, PharmD, RPh, MSPH, MBA; Casey Fitzpatrick, PharmD, BCPS; Kristin Darin, PharmD, BCPS; Rabiah Dys, PharmD;
Karen Lee, PharmD, RPh, BCPS; Carly Giavatto, PharmD; Ana Lopez Medina, PharmD, PhD; Jessica Mourani, PharmD.
The study helped answer the following questions: HSSP teams can help address patients’ unmet health-related social needs (HRSNs). Yet, screening tools are limited. What is the ideal screening and referral process to help HSSP teams better understand patients’ SDOH and identify patients’ unmet HRSNs?
One insight we learned: The study evaluated a screening tool for people living with type 2 diabetes mellitus (T2DM) and HIV. These conditions have several SDOH-related disparities that can impact clinical outcomes. The team found that HRSNs remain prevalent in these cohorts, indicating that adopting the screening tool could be beneficial.
The findings: Download the poster.
ISPOR 2024 was May 5-8, 2024, in Atlanta. Learn more about CPS' clinical outcomes research and pharmacy success: https://perspectives.cps.com/tag/outcome-studies.